Background and Aim: The fibrosis stage of non-alcoholic fatty liver disease (NAFLD) is closely associated with long-term prognosis, including liver-related mortality. However, it is not yet clear whether noninvasive fibrosis markers can predict the incidence of nonliver-related complications in Japanese NAFLD. In this study, we clarified the prognosis of NAFLD patients, including non-liver-related diseases, based on hepatic pathology and noninvasive fibrosis markers. Methods: A total of 246 Japanese patients with NAFLD diagnosed by liver biopsy were enrolled. We investigated their prognosis based on hepatic pathology and noninvasive fibrosis markers. Results: When these patients were categorized based on the severity of liver fibrosis as F0-2 (n = 196) and F3-4 (n = 50), the patients with F3-4 had significantly poorer prognosis in overall survival rates and all complications (P < 0.05). The fibrosis-4 (FIB-4) index was useful to predict overall survival and the incidence of hepatocellular carcinoma and liver cirrhosis (LC)-related complications but not extrahepatic malignancies. Multiple logistic regression analyses revealed the following risk factors: total bilirubin ≥ 1.2 (hazard ratio [HR] 6.362, 95% confidence interval [CI] 1.393-29.052) and severe liver fibrosis (HR 6.512, 95% CI 1.433-29.592) for overall survival; liver fibrosis (F3-4) (HR 13.370, 95% CI 2.775-64.427) for hepatocellular carcinoma; FIB-4 index (HR 26.560,) for LC-related complications, and liver inflammation (A2-3) (HR 4.214, 95% CI 1.354-13.116) for extrahepatic malignancies. Conclusions: Severe liver fibrosis was associated not only with the hepatocarcinogenesis and LC-related complications but also with extrahepatic malignancies. The FIB-4 index was useful for predicting liver-related diseases but had limitations in predicting extrahepatic malignancies.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, and its prevalence is increasing worldwide.
1 A recent population-based screening study in Asia found that approximately 41% of men and 18% of women had NAFLD. 2, 3 As the number of patients with obesity and diabetes mellitus rises, the incidence of NAFLD is expected to further increase.
Histologically, NAFLD is classified into either non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH). The histologic findings of NAFL demonstrate hepatic steatosis without evidence of hepatocellular injury (e.g. lobular inflammation and/or ballooning of hepatocytes), and patients with NAFL usually have a good prognosis. Conversely, the histologic findings of NASH are characterized by the presence of hepatic steatosis and inflammation with distinctive hepatocyte injury. Patients with NASH are at increased risk of developing life-threatening conditions such as liver cirrhosis and hepatocellular carcinoma (HCC).
Recent paired-liver biopsy studies suggest that NAFL can progress to NASH and clinically significant fibrosis. 4 In addition, NAFLD patients with severe fibrosis are at increased risk of not only liver-related diseases but also cardiovascular events and other malignancies. [5] [6] [7] [8] The fibrotic status of the liver of an NAFLD patient is the most important determinant of long-term prognosis, regardless of whether the pathological diagnosis is NASH or NAFL. 5, 9 Thus, the development of surrogate markers for evaluating liver fibrosis in NAFLD should lead to more accurate determinations of the prognosis of NAFLD patients.
In order to predict liver fibrosis in chronic hepatitis, including viral hepatitis and NAFLD, various noninvasive methods have been developed, such as serum markers and imaging for measuring liver stiffness. 10, 11 Of these, the fibrosis-4 (FIB-4) index and NAFLD fibrosis score (NFS) are mostly used to exclude and diagnose advanced fibrosis in NAFLD. [12] [13] [14] Recent reports demonstrated that these noninvasive markers could predict not only liver fibrosis but also liver-related prognosis (i.e. hepatocarcinogenesis and recurrence of HCC after treatment) in patients with chronic hepatitis. 15, 16 However, it remains unclear whether these laboratory markers can also serve as biomarkers capable of predicting the outcomes for Japanese NAFLD patients, including extrahepatic manifestations. We therefore aimed to study mortality as well as the prognosis of both liver-related and non-liver-related diseases based on hepatic pathology and noninvasive laboratory markers and to assess biomarkers associated with them among biopsy-proven Japanese NAFLD patients.
Materials and methods
Patients. Between January 1999 and December 2014, a total of 301 patients underwent liver biopsy for the diagnosis of NASH at Nagoya University Hospital, Ogaki Municipal Hospital, and Toyota Kosei Hospital. Fifty-five patients were excluded for the following reasons: (i) other causes of chronic liver disease (e.g. primary biliary cholangitis and autoimmune hepatitis), n = 7; (ii) suspected drug-induced NASH, n = 2; (iii) insufficient evaluation of NASH/NAFL classification on pathological findings, n = 4; (iv) insufficient follow-up, incomplete data, n = 16; (v) the history of liver/non-liver-related complications, n = 10; and (vi) follow-up duration of less than 1 year, n = 16 ( Fig. 1) . The study protocol was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Nagoya University Hospital (no. 2017-0524).
Diagnosis of non-alcoholic fatty liver disease. Nonalcoholic fatty liver disease was diagnosed based on the guidelines established by the American Association for the Study of Liver Diseases, 17 as follows: (i) fatty change of the liver was observed by imaging; (ii) no marked alcohol drinking habit was present (ethanol intake of < 210 g per week for men and < 140 g per week for women); (iii) no presence of other factors inducing fatty change of the liver; and (iv) no chronic liver disease with clear etiology, such as viral infection (hepatitis C virus or hepatitis B virus), primary biliary cholangitis, or autoimmune hepatitis.
Histopathological examination of the liver and definitions of non-alcoholic steatohepatitis/nonalcoholic fatty liver. Percutaneous liver biopsy was performed with a 16-17 gauge needle under ultrasonographic guidance. The liver biopsy specimens were immediately fixed in 10% formalin and embedded in paraffin. An adequate liver biopsy sample was defined as a specimen with a length of > 1.5 cm. Experienced pathologists, specialized in NAFLD, evaluated the specimens. Pathological evaluations were carried out without knowledge of clinical data. Patients were histologically diagnosed as NASH based on the criteria of Younossi et al., 18 as follows: (i) any degree of steatosis along with centrilobular ballooning and/or Mallory-Denk bodies or (ii) any degree of steatosis along with centrilobular pericellular, pericellular/perisinusoidal, or bridging fibrosis. The severity of hepatic inflammatory grade and fibrosis stage was scored on the basis of the scale proposed by Brunt et al.
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: grade 1, mild inflammation; grade 2, moderate inflammation; and grade 3, severe inflammation. Stage 0, normal connective tissue; stage 1, pericellular or perivenular fibrosis in zone 3 (pericentral vein area); stage 2, zone 3 perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis; stage 3, bridging or septal fibrosis; and stage 4, cirrhosis. Mild fibrosis was defined as stages 0-2 fibrosis (F0-2), and severe fibrosis was defined as stages 3-4 fibrosis (F3-4).
Definitions of hypertension, diabetes mellitus, and dyslipidemia. Hypertension was defined as systolic blood pressure ≥ 135 mmHg or diastolic blood pressure ≥ 85 mmHg after 5 min of rest or use of any antihypertensive medication. Diabetes mellitus was diagnosed based on the criteria of the American Diabetes Association, 20 as follows: (i) casual plasma glucose ≥ 200 mg/dL, (ii) fasting plasma glucose ≥ 126 mg/dL, (iii) 2-h post-glucose load ≥ 200 mg/dL (oral glucose tolerance test), or (iv) use of any antihyperglycemic medication. Dyslipidemia was Figure 1 Flowchart of the patient selection process. HCC, hepatocellular carcinoma; NAFL, non-alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
defined as low-density lipoprotein cholesterol ≥ 140 mg/dL, highdensity lipoprotein cholesterol < 40 mg/dL, triglycerides ≥ 150 mg/dL, or treatment with lipid-lowering medication.
Calculation of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score. The FIB-4 index and NFS were calculated at the time of liver biopsy using the following formula: 
The asterisk ( * ) indicates that impaired fasting glucose is defined as fasting blood glucose ≥ 110 mg/dL.
14 The cut-off values for FIB-4 index and NFS were 2.67 and À1.455, respectively, as defined based on previous reports 14, 22 and the distribution of patients.
Surveillance, diagnosis of complications, and causes of death. Hepatocellular carcinoma surveillance was performed every 6 to 12 months using ultrasonography and/or blood tests and included measurement of the tumor marker alpha fetoprotein. If a nodular lesion was detected by ultrasonography or a tumor marker was elevated, additional imaging studies (computed tomography, magnetic resonance imaging, or both) were conducted. The diagnosis of HCC was based on imaging characteristics specified by the guidelines of the American Association for the Study of Liver Diseases. 23 Liver-related complications were defined as jaundice, hepatic encephalopathy, esophageal or gastric varices, and ascites accompanied with liver cirrhosis. Malignancies other than HCC and liver-related complications were initially detected based on clinical symptoms, abnormal surveillance data, medical check-ups (in the community or workplace), or physician assessments. The definition of cardiovascular disease (CVD) was based on the onset of apparent symptoms or treatment interventions for diseases related to the heart or large blood vessels, including myocardial infarction, angina pectoris, stroke, abdominal aortic aneurysm, and congestive heart failure. We confirmed that patients did not have a history of malignancies or CVD at the start of follow-up. Causes of death were categorized by specialists at our hospital or by family physicians, if patients died outside of our hospitals. All determinations of causes of death were performed retrospectively by collecting and analyzing data from all patient medical records.
Statistical analysis. Continuous variables were expressed as medians (interquartile range). Categorical variables were expressed as numbers (percentages). Associations between noninvasive fibrosis markers and pathological fibrosis were analyzed using Spearman's rank correlation. An actuarial analysis of the cumulative incidence of hepatocarcinogenesis, liver-related complications other than HCC, extrahepatic malignancies, and CVD was performed using the Kaplan-Meier method. Differences across groups were compared using a log-rank test. Statistical significance was defined as P < 0.05. Cox proportional hazards models using the forward selection method were performed to estimate hazard ratios (HRs) using the parameters selected as significant factors (P < 0.05) by univariate analysis. We used the lower or upper limit of the reference values at Nagoya University Hospital as cut-off values for laboratory data. Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University; Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). 24 
Results
Patient characteristics. Characteristics of the study patients are shown in Table 1 . The median age was 55 years, and there was a predominance of men (52.0%). The median body mass index was 26. Prognosis based on hepatic pathology. Figure 2 shows the overall survival and the incidence curves of liver-related and non-liver-related diseases based on hepatic pathology. When patients were categorized as NAFL (n = 90) or NASH (n = 156) group, the incidence rates of HCC and LC-related complications in the NASH group were significantly higher than in the NAFL group (HCC, P = 0.023; liver-related complications, P = 0.012). Conversely, overall survival, the incidence of extrahepatic malignancies, and CVD did not differ between patients with NAFL versus NASH (overall survival, P = 0.327; extrahepatic malignancies, P = 0.111; and CVD, P = 0.668).
We next focused on the severity of fibrosis in this population (F0-2 n = 196 and F3-4 n = 50; Fig. 3 ). The overall survival rate of patients with severe liver fibrosis was significantly lower than that of patients with mild fibrosis (P = 0.006). The incidence rates of HCC, LC-related complications, and extrahepatic malignancies in patients with severe liver fibrosis were significantly higher than those of patients with mild fibrosis (HCC, P < 0.001; LC-related complications, P = 0.015; and extrahepatic malignancies, P = 0.003). The incidence rate of CVD was comparable between the two groups (P = 0.541). We investigated the prognosis based on the severity of hepatic inflammation (A1 n = 151 and A2-3 n = 95; Fig. S2 ). The incidence rates of HCC, LC-related complications, and extrahepatic malignancies in patients with severe hepatic inflammation (A2-3) were significantly higher than those of patients with mild inflammation (A1), as well as liver fibrosis (HCC, P = 0.021; LCrelated complications, P = 0.044; and extrahepatic malignancies, P = 0.003). However, there were no significant differences for overall survival and incidence of CVD between these two groups. Table S1 shows the causes of death according to the severity of fibrosis. Eight of 246 patients (3.3%) died during the follow-up period. All patient deaths in the severe fibrosis group were due to liver-related causes, including HCC and rupture of esophageal varices. The rate of liver-related deaths in patients with mild fibrosis was 50%. Table S2 shows the frequency and type of events that occurred during follow-up. The majority of extrahepatic malignancies in both mild and severe fibrosis groups were breast cancer and digestive malignancies.
Prognosis based on noninvasive fibrosis markers. Next, we examined whether noninvasive fibrosis markers, FIB-4 index and NFS, could predict the prognosis of NAFLD patients in place of pathological liver fibrosis. We confirmed that both FIB-4 index and NFS were significantly correlated with pathological fibrosis based on Spearman's rank correlation (FIB-4 index, r = 0.529; NFS, r = 0.353, P < 0.001; Fig. S3 ). Figure 4 shows the survival rate and cumulative incidence rates of liver-related and non-liver-related diseases based on the FIB-4 index. When patients were categorized based on FIB-4 index as < 2.67 (n = 195) and ≥ 2.67 (n = 51), the FIB-4 index ≥ 2.67 group displayed significantly lower overall survival rates and significantly higher incidence of HCC and LC-related complications than the FIB-4 index < 2.67 group (overall survival, P = 0.018; HCC, P < 0.001; and LC-related complications, P < 0.001). However, the incidence rates of extrahepatic malignancies and CVD were comparable between the two groups (extrahepatic malignancies, P = 0.183 and CVD, P = 0.505). In an additional analysis of prognosis, we assessed the groups based on NFS (Fig. S4) . This marker was able to predict overall survival and the incidence of HCC and LC-related complications as well as the FIB-4 index, but it was not able to predict extrahepatic malignancies and CVD. Table S3 shows overall survival and incidental rates of liver-related and non-liver-related diseases in 5 and 10 years.
Factors associated with mortality and prognosis in patients with non-alcoholic fatty liver disease. Factors significantly associated with mortality and the incidences of liver-related and non-liver-related diseases in the univariate analysis are listed in Tables S4-S8 . In multivariate analysis using these selected factors, the following parameters were selected as independent risk factors: total bilirubin ≥ 1.2 mg/dL (HR 6.362; 95% CI 1.393-29.052; P = 0.017) and liver fibrosis ≥ F3 (HR 6.512; 95% CI 1.433-29.592; P = 0.015) for survival; liver fibrosis ≥ F3 (HR 13.370; 95% CI 2.755-64.427; P = 0.001) for HCC; FIB-4 index ≥ 2.67 (HR 26.560; 95% CI 3.320-212.494; P = 0.002) for LC-related complications; and liver inflammation ≥ A2 (HR 4.214; 95% CI 1.354-13.116; P = 0.013) for extrahepatic malignancies. Univariate analysis indicated that the only significant risk factor for CVD was hypertension (HR 3.949; 95% CI 1.067-14.618; P = 0.040) ( Table 2) .
Discussion
When compared with the general population of the same age and sex, patients with NAFLD were found to have a significantly higher mortality rate. 9, 25 Some patients with NAFLD, especially Continuous variables are expressed as medians (interquartile range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, Creactive protein; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; NFS, NAFLD fibrosis score; γ-GTP, γ-glutamyl transpeptidase.
Noninvasive fibrosis markers for non-alcoholic fatty liver disease T Ito et al. The incidence rates of hepatocellular carcinoma and liver cirrhosis-related complications in the NASH group were significantly higher than in the NAFL group. Overall survival, incidence rates of extrahepatic malignancies, and cardiovascular disease were comparable between these groups. [ ] F3-4 n = 50). The overall survival rate in patients with severe liver fibrosis was significantly lower than that of patients with mild fibrosis. The incidence rates of hepatocellular carcinoma, liver cirrhosisrelated complications, and extrahepatic malignancies in the severe fibrosis group were significantly higher than in the mild fibrosis group. The incidence rate of cardiovascular disease was comparable between the two groups.
T Ito et al.
Noninvasive fibrosis markers for non-alcoholic fatty liver disease those with severe fibrosis, have a high risk of liver-related disease, such as hepatic encephalopathy, rupture of esophageal and gastric varices, and HCC. However, only a minority of NAFLD patients progress to advanced liver disease or liver-related death. Kawamura et al. reported that the annual liver carcinogenic rate in Japanese NAFLD patients was only 0.043%. 26 NAFLD typically develops as a result of metabolic disorders, such as metabolic syndrome, diabetes, and dyslipidemia, and is one facet of a multisystem disorder with chronic general inflammation. Accordingly, NAFLD is associated with various complications induced by systemic inflammation, such as CVD, chronic kidney disease, and extrahepatic malignancies. 27 It is essential to focus on both intrahepatic and extrahepatic complications during follow-up of NAFLD patients. [ ] ≥ 2.67, n = 51). The overall survival rate in FIB-4 index < 2.67 group was significantly higher than in the FIB-4 index ≥ 2.67 group, and the incidence rates of hepatocellular carcinoma and liver cirrhosis-related complications in the FIB-4 index < 2.67 group were significantly lower than in the FIB-4 index ≥ 2.67 group. The incidence rates of extrahepatic malignancies and cardiovascular disease were comparable between the two groups. CI, confidence interval; FIB-4, fibrosis-4; LC, liver cirrhosis; N.S., not significant.
Noninvasive fibrosis markers for non-alcoholic fatty liver disease T Ito et al.
In this study, the progression of liver fibrosis was associated with mortality, hepatocarcinogenesis, LC-related complications, and extrahepatic malignancies. The popular noninvasive liver fibrosis markers, FIB-4 index and NFS, were useful for predicting the occurrence of liver-related diseases but were limited in their ability to predict extrahepatic malignancies. The FIB-4 index and NFS are complex markers calculated using several parameters, including age, liver transaminase, and platelet counts. Originally, both the FIB-4 index and NFS were developed as predictive markers of intrahepatic fibrosis, not systemic inflammation and fibrosis. Conversely, liver fibrosis is generated from systemic chronic inflammation because NAFLD is a multisystem disease that affects many extrahepatic organ systems. 27, 28 The discrepancy between pathological fibrosis and these noninvasive markers might be due to whether FIB-4 or NFS reflects only intrahepatic inflammation and fibrosis or systemic inflammation.
Very recently, Tada et al. reported the utility of NFS and FIB-4 index for assessing mortality from various non-liver-related causes, including extrahepatic malignancies, in a large cohort study among Japanese patients with non-biopsy-proven NAFLD. 29 Key differences of that report and our study were as follows: (i) the outcome: mortality or incidence of non-liverrelated diseases and (ii) the study population: NAFLD diagnosed with ultrasonography or biopsy-proven NAFLD. In this study, eight patients died during follow-up, with causes of death for six of the patients due to liver-related diseases. Additionally, most extrahepatic malignancies that occurred in our study were cured or controlled for a long period after diagnosis (data not shown). By contrast, the majority of the mortality in the report by Tada et al. was due to non-liver-related diseases (95.0%). The patients in our study were followed up strictly after biopsy, which might decrease the incidence rates of extrahepatic malignancies compared with Tada's report. A larger cohort study using noninvasive fibrosis markers in biopsy-proven NAFLD patients to investigate both mortality and incidence rates is needed.
In this study, 11 (68.8%) of the extrahepatic malignancies were breast and colorectal cancers. Previous reports showed that NAFLD was associated with the development of HCC, colorectal cancer in males, and breast cancer in females as extrahepatic malignancies, 30 which was consistent with our results. Both colorectal cancer and breast cancer have been reported to have an association with obesity and chronic inflammation accompanied by insulin resistance. 31, 32 Our study demonstrated that both pathological inflammation and fibrosis in the liver were associated with the incidence of extrahepatic malignancies by Kaplan-Meier analysis, and hepatic inflammation was selected as an independent risk factor in multivariate analysis. Specifically, hepatic inflammation could discriminate the incidence rate of extrahepatic malignancies earlier than hepatic fibrosis when comparing these incidence curves. These results suggest that hepatic inflammation preceding fibrosis may be a surrogate marker for the earlier prediction of extrahepatic carcinogenesis in NAFLD patients.
Our study also revealed that both pathological fibrosis and noninvasive fibrosis markers were not able to predict the incidence of CVD. Previous reports showed that high values for noninvasive fibrosis markers was a significant predictor of mortality, mainly from cardiovascular causes, in the USA. 33 However, there were few reports to assess the relationship between NAFLD and CVD events in Japanese patients. In general, the incidence rate of CVD-related clinical events of North American and Asian patients is different, and the mortality rate related to CVD in Japan is lower than in North America. 34 This is due to the differences in lifestyle and CVD risk factors between these regions. For instance, Japanese patients with CVD were more likely to be older, have a history of smoking, and have diabetes mellitus. American patients were more obese and had a greater prevalence of atherosclerotic processes and hypertension. 35 However, we have no detailed information on smoking history in our study. Although the risk factors were not detected with multivariate analysis in this study, the differences of race and lifestyle might have impacted our results.
This study has several limitations, including a retrospective and patient selection bias. The recommendation of a liver biopsy for NAFLD patients was dependent on their doctors. It is difficult to safely perform liver biopsies on very elderly people or patients with decompensated cirrhosis, resulting in fewer cirrhosis patients in this study's population. Moreover, we did not evaluate other risk factors related to NASH differentiation and hepatocyte apoptosis, such as the gene encoding patatin-like phospholipase domaincontaining 3 related to NASH differentiation and cytokeratin-18 fragments. With regard to analysis, the number of event in the present study was relatively few to draw a firm conclusion, especially overall survival. However, the strengths of this study included pathological findings and the data of long-term follow-up period.
In conclusion, this study showed that the progression of pathological liver fibrosis severity was associated with mortality and the incidence of HCC, LC-related complications, and extrahepatic malignancies. The noninvasive fibrosis markers, FIB-4 index and NFS, were useful for predicting mortality and the incidence of liver-related disease, and patients with low values for these markers had lower incidences of HCC and LC-related complications. However, FIB-4 and NFS were limited in their ability to predict the incidence of non-liver-related diseases. Clinicians following NAFLD patients need to understand the utility and limitations of these noninvasive fibrosis markers.
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